Glaukos outlines $680M-$700M 2026 net sales as iDose TR seen at $275M-$280M

The guidance for 2026 net revenue is $680M-$700M, representing approximately 20-25% growth compared to the same period last year, with iDose TR sales projected at $275M-$280M, exceeding previous estimates by 15-20%. In particular, iDose TR is expected to be a key growth driver with rapid market entry following FDA approval, contributing to the stabilization of Glaukos's performance. However, there are concerns about entering an overbought zone with an RSI of 72.8, and the potential for further price increases may be limited depending on how future performance is reflected in the market.

The acceleration of commercialization following the FDA approval of iDose TR and the upward revision of the 2026 earnings guidance are key catalysts reaffirming Glaukos' growth story. iDose TR can achieve rapid market entry through the FDA 510(k) pathway after FDA approval, differentiating itself with superior efficacy and safety as an implant for intraocular pressure control following cataract surgery compared to existing treatments. The 2026 earnings guidance exceeds market expectations, and notably, the projected sales for iDose TR significantly surpass previous estimates.